ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,537.02
0.51%
US Tech 100
19,641.60
0.83%
Dow Jones
39,308.00
-0.06%
Brent Oil
86.705
-0.24%
Bitcoin
57,443.57
-4.52%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. BeiGene Ltd (BGNE)

  7. BeiGene Ltd (BGNE) News

BGNE

BeiGene (BGNE)

BeiGene Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BGNE
DateTimeSourceHeadlineSymbolCompany
01/05/20234:05PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BGNEBeiGene Ltd
01/04/20237:07AMBusiness WireBeiGene to Present at the J.P. Morgan 41st Annual Healthcare ConferenceNASDAQ:BGNEBeiGene Ltd
12/30/20229:00AMBusiness WireBeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor TislelizumabNASDAQ:BGNEBeiGene Ltd
12/19/20224:17PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BGNEBeiGene Ltd
12/15/20225:05PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BGNEBeiGene Ltd
12/13/202210:00AMBusiness Wire BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASHNASDAQ:BGNEBeiGene Ltd
12/12/20227:30AMTipRanksAnalysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Acrivon Therapeutics, Inc. (ACRV) and Affimed (AFMD)NASDAQ:BGNEBeiGene Ltd
12/09/20227:00AMBusiness WireBeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and SurvivorsNASDAQ:BGNEBeiGene Ltd
12/08/20222:10PMPR Newswire (US)Phanes Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate PT199 in combination with TislelizumabNASDAQ:BGNEBeiGene Ltd
11/25/202210:37AMValueWalkThese Are the Five Best and Worst Performing Healthcare Stocks in October 2022NASDAQ:BGNEBeiGene Ltd
11/25/20226:05AMTipRanksSVB Securities Keeps Their Buy Rating on BeiGene (BGNE)NASDAQ:BGNEBeiGene Ltd
11/22/20224:08PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BGNEBeiGene Ltd
11/22/20228:30AMBusiness WireBeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022NASDAQ:BGNEBeiGene Ltd
11/20/202211:20PMTipRanksAnalysts Offer Insights on Healthcare Companies: Atreca (BCEL), Apellis Pharmaceuticals (APLS) and BeiGene (BGNE)NASDAQ:BGNEBeiGene Ltd
11/17/20225:14PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BGNEBeiGene Ltd
11/17/20227:00AMBusiness WireBeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)NASDAQ:BGNEBeiGene Ltd
11/15/20227:00AMBusiness WireBeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer CareNASDAQ:BGNEBeiGene Ltd
11/10/20227:00AMBusiness WireBeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood CancersNASDAQ:BGNEBeiGene Ltd
11/09/20227:13AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BGNEBeiGene Ltd
11/09/20227:07AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BGNEBeiGene Ltd
11/09/20227:00AMBusiness WireBeiGene Reports Third Quarter 2022 Financial ResultsNASDAQ:BGNEBeiGene Ltd
11/07/20224:07PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BGNEBeiGene Ltd
11/04/20227:00AMBusiness WireBeiGene to Present at Upcoming Investor ConferencesNASDAQ:BGNEBeiGene Ltd
11/03/20229:00AMBusiness WireBeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH MeetingNASDAQ:BGNEBeiGene Ltd
11/02/202210:35AMDow Jones NewsBeiGene Shares Rise 5% After EC Marketing Authorization for BrukinsaNASDAQ:BGNEBeiGene Ltd
11/02/20227:00AMBusiness WireBeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone LymphomaNASDAQ:BGNEBeiGene Ltd
10/26/20227:00AMBusiness WireBeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin AmericaNASDAQ:BGNEBeiGene Ltd
10/14/20224:10PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BGNEBeiGene Ltd
10/14/20226:30AMBusiness WireBeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLLNASDAQ:BGNEBeiGene Ltd
10/13/20228:35AMTipRanksBeiGene (BGNE) Gets a Buy from Morgan StanleyNASDAQ:BGNEBeiGene Ltd
 Showing the most relevant articles for your search:NASDAQ:BGNE

Your Recent History

BIT
P201N2
NLBNPIT201N2 20991231 21...
BIT
UC4VD7
Unicredit Bank
BIT
P1U9S0
BNP Paribas Issuance
NASDAQ
VIIAW
7GC
BIT
UC24CM
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved